Safety and Clinical Role of First‑Generation Antidepressants

Classification

• First‑generation antidepressants are comprised of two principal classes—tricyclic antidepressants (TCAs) and monoamine‑oxidase inhibitors (MAOIs)—used for the treatment of major depressive disorder. 1

Safety Concerns

• TCAs carry a high risk of fatality in overdose, making them a critical safety concern when prescribed for depressive patients. 1

Comparative Efficacy and Toxicity

• Second‑generation agents (selective serotonin reuptake inhibitors, serotonin‑norepinephrine reuptake inhibitors, and serotonin‑serotonin‑norepinephrine reuptake inhibitors) have demonstrated comparable efficacy to first‑generation antidepressants while exhibiting markedly lower toxicity in overdose, leading to the widespread replacement of first‑generation drugs. 1

Guideline Recommendations

• TCAs are not recommended as first‑line therapy for depression because they produce a greater burden of adverse effects, possess a higher overdose risk, and have not shown superiority over second‑generation antidepressants. 3